<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288339</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD-0903</org_study_id>
    <secondary_id>2009-017331-18</secondary_id>
    <nct_id>NCT01288339</nct_id>
  </id_info>
  <brief_title>Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer</brief_title>
  <acronym>PULSE</acronym>
  <official_title>An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the progression free survival for subjects treated with panitumumab in
      combination with a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin
      (FOLFOX) as first-line chemotherapy regimen for subjects with metastatic colorectal cancer
      with WT (wild type) KRAS according to the IGFRp (protein receptor insulin growth factor) and
      MMP-7 (Matrilysin) expression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By transactivation, phosphorylated insulin growth factor receptor I (p-IGF-IR) can activate
      epidermal growth factor receptor (EGFR). Matrilysin (MMP-7), can activate IGF-IR
      (insulin-like growth factor receptor ) by degrading IGFBP-3 (Insulin-like growth
      factor-binding protein 3) and releasing IGF-I (Insulin-like growth factor 1). Concomitant
      expression of MMP-7 and p-IGF-IR (using a specific monoclonal antibody (p-1316) recognizing
      the phosphorylated carboxy-terminal part of the IGF-IR) (DP (Double Positivity)) correlates
      with poor prognosis in WT KRAS patients treated with anti-EGFR antibodies plus irinotecan.The
      primary objective of this trial is to estimate the progression free survival (PFS) by DP
      (Double Positivity)immunohistochemistry (IHC) expression in patients with wild-type KRAS mCRC
      (metastatic colorectal cancer)treated with panitumumab and mFOLFOX6. Two groups are
      established by DP status (MMP7+/p-IGF-IR+ vs. MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or
      MMP7-/p-IGF-IR-). With a power of 80% and a bilateral alpha level of 0.05, assuming an
      accrual period of 12 months (m) and a follow-up period of 18 m, 40 patients are planned to be
      included in each group to detect a Hazard Ratio of 2. The median PFS of the DP group is
      expected to be 6 m and the total number of expected events is 56. Secondary objectives
      include disease control rate, duration of response, time to response and survival according
      the DP status. Neither interim analysis nor multiple comparison adjustment is
      planned.Treatment: Both groups will receive panitumumab 6 mg/kg and mFOLFOX6 every 2 weeks.
      If patients have not progressed after 6 m of treatment they will continue with panitumumab
      monotherapy until disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2010</start_date>
  <completion_date type="Actual">February 13, 2015</completion_date>
  <primary_completion_date type="Actual">February 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival time according to the MMP7 status (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To estimate the PFS by DP immunohistochemistry (IHC) expression in patients with wild-type KRAS mCRC treated with panitumumab and mFOLFOX6. Two groups are established by DP status (MMP7+/p-IGF-IR+ vs. MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR-).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from first confirmed objective response to radiologic disease progression per modified RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization date to date of first confirmed objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TtTF)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from enrolment to the date the decision was made to end the treatment phase for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of either a confirmed CR or PR per modified RECIST criteria. CRs or PRs will be confirmed no less than 28 days after the criteria for response are first met. All subjects without a confirmed response will be considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of either a confirmed CR or PR or stable disease (SD) while in the treatment phase; subjects prematurely discontinuing without a post baseline tumor response assessment or subjects with an observed response that is not confirmed will be considered non-responders otherwise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization date to date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization date to date of radiologic disease progression per modified RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stable Disease (DoSD)</measure>
    <time_frame>5 years</time_frame>
    <description>Calculated for only those subjects with a best response of SD during the treatment period, time from enrolment to date of first observed PD or death due to PD (whichever comes first) in either the combination or monotherapy phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence and severity of AEs (Common Toxicity Criteria version 3.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular predictive markers for response.</measure>
    <time_frame>5 years</time_frame>
    <description>Molecular predictive markers for response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab + FOLFOX (DP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panitumumab + FOLFOX (no-DP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab + FOLFOX (DP)</intervention_name>
    <description>Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.</description>
    <arm_group_label>Panitumumab + FOLFOX (DP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab + FOLFOX (no-DP)</intervention_name>
    <description>Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.</description>
    <arm_group_label>Panitumumab + FOLFOX (no-DP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman ≥ 18 years.

          -  Competent to comprehend, sign, and date an IEC-approved (Ethics Committee) informed
             consent form

          -  Histologically-confirmed metastatic adenocarcinoma of the colon or rectum by the
             investigator.

          -  Wild Type K-RAS colorectal cancer determined by the designated Central Laboratory
             prior to inclusion in the study in the primary tumor and/or at least one metastasis.

          -  At least 1 uni-dimensionally measurable lesion of at least &gt; 10 mm with spiral CT per
             modified RECIST criteria 1.1. (Response Evaluation Criteria In Solid Tumors)

          -  Patients with the following characteristics will be included:

               1. Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or
                  capecitabine +/- radiotherapy with a disease-free interval &gt; than 6 months after
                  its completion.

               2. Recurrence after adjuvant treatment with oxaliplatin +/- radiotherapy with a
                  disease-free interval &gt; than 12 months

               3. De novo diagnosis of the disease.

          -  Eastern Cooperative Oncology Group performance status of 0 or 1.

          -  Life expectancy ≥ 3 months

          -  Adequate bone marrow function

          -  Adequate Hepatic and metabolic functions

          -  Adequate Renal function

          -  Magnesium &gt; LLN (Lower limit of Normal)

        Exclusion Criteria:

          -  Patients they have received prior systemic therapy for the treatment of metastatic
             colorectal carcinoma.

          -  Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr
             tyrosine kinase inhibitors (eg, erlotinib) or EGFR signal transduction inhibitors.

          -  Patients who had resection of metastatic disease

          -  Central nervous system/brain metastases

          -  Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of
             the skin or pre-invasive cervical cancer.

          -  Unresolved toxicities from prior systemic therapy that, in the opinion of the
             investigator, does not qualify the patient for inclusion

          -  Presence of peripheral neuropathy (Common Toxicity Criteria (CTC) version 3.0 &gt; grade
             1), and of serious nonhealing wound, ulcer, or bone fracture.

          -  Hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg,
             bevacizumab) ≤ 30 days before inclusion

          -  Significant cardiovascular disease including unstable angina or myocardial infarction
             within 12 months before initiating study treatment or a history of ventricular
             arrhythmia.

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline chest CT scan

          -  Treatment for systemic infection within 14 days before initiating study treatment

          -  Acute or sub-acute intestinal occlusion and /or active inflammatory bowel disease or
             other bowel disease causing chronic diarrhea (defined as &gt; 4 loose stools per day).

          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,
             chronic active hepatitis B infection

          -  Any investigational agent within 30 days before enrollment

          -  Subject who is pregnant or breast feeding

          -  Surgery (excluding diagnostic biopsy or central venous catheter placement) and/or
             radiotherapy within 14 days prior to inclusion in the study.

          -  Woman or man of childbearing potential not consenting to use adequate contraceptive
             precautions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Maurel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Martín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu i Sant Pau de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonia Salud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova de Lleida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Arrivi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Llatzer de Mallorca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Hernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intitut Català d' Oncologia (ICO) de Girona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ólbia Serra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de l'Hospitalet de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carles Pericay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporació Sanitaria Parc Taulí de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Busquier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorcio Hospitalario Provincial de Castellon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Fernandez-Martos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Oncología de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Aparicio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria José Safont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carles Bosch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Dr. Peset de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Gallego, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial General Universitario de Elche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Carmona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial Morales Meseguer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaume Feliu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial Universitario La Paz de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Ruíz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Fuenlabrada de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Casado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Infanta Sofía de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Cubedo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juana Maria Cano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial General de Ciudad Real</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet de Zaragoza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Jorge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Xeral Cies de Vigo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herminio Manzano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Dureta de Mallorca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Rodríguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uriel Bohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial Dr. Negrin de Las Palmas de Gran Canaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miriam Zorrilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Logroño</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Vera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial de Burgos. Hospital General Yague</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santiago Albiol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de l'Esperit Sant de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Carlos Méndez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Oncológico de Galicia (La Coruña)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Javier Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sant Pau i Santa Tecla de Tarragona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial General de l'Hospitalet de Barcelona</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08906</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí de Barcelona</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de l'Esperit Sant</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellon</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellon</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases de Mallorca</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Illes Balears</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Son Llatzer de Mallorca</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial de Logroño</name>
      <address>
        <city>Logroño</city>
        <state>La Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz de Madrid</name>
      <address>
        <city>Madrid</city>
        <state>Madrdi</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cies de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asitencia de Burgos. Hospital General Yague</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia (ICO) de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galícia</name>
      <address>
        <city>La Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Dr. Negrin de Las Palmas de Gran Canaria</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofía de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28072</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial de Sant Pau i Santa Tecla de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <zip>43003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

